Dr Reddys signs Russian deal


To collaborate with R-Pharm of Moscow

Indian pharmaceutical firm Dr Reddys Laboratories has formed a manufacturing partnership with R-Pharm of Russia in a bid to strengthen its presence in the region.

The deal will entail licensing of manufacturing expertise of products by Dr Reddys, local manufacturing of products in Russia, co-development of high technology products and knowledge sharing between both firms at regular intervals.

Satish Reddy, managing director and chief operating officer of Dr Reddy’s, said the collaboration would help the firm deepen its engagement with Russia, which is one of its key markets.

The agreement will also allow Dr Reddys to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company and enable the firm to import and market R-Pharm products in India according to agreed terms, he said.

Alexey Repik, chairman of Moscow-based Rpharm, added: ‘This agreement helps address unmet medical needs in important therapeutic areas and make medicines more affordable to patients in Russia.

‘It also pioneers a new way of collaboration between an Indian and a Russian pharmaceutical company. It is a change of approach from just imports of finished products to deep integration in technology, manufacturing, marketing and knowledge sharing.’

Dr Reddys entered the Russia market in 1992 and Omez, Nise, Ketorol and Ciprolet are now the firm’s top four brands in the Russian market.